Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Patients had significant reduction in urinary albumin-to-creatinine ratio (UACR) in the first six months of using dapagliflozin.
Read More »Using Dapagliflozin for Reduction in Adverse Renal and CV Outcomes
Don’t Forget our Patients with Type 1 Diabetes
Cardiovascular and renal disease burdens also occur in type 1 diabetes.
Read More »The Link Between Type 2 Diabetes and Heart Failure
A Mendelian Randomization found a correlation between type 2 diabetes and heart failure, utilizing genetic markers.
Read More »ADA 81st Symposium: The Combination of SGLT-2 inhibitors and GLP-1 Receptor Agonists
Can a new potential treatment combining an SGLT-2 and a GLP-1 RA mitigate cardiometabolic risk?
Read More »Ertugliflozin Proved Effective in Patients with Type 2 Diabetes and ASCVD
A VERTIS CV sub study showed significant improvements in glycemic control after adding ertugliflozin to insulin-based regimens.
Read More »Mental Disorders Complicate the Treatment of Patients with Diabetes
Individuals with mental health disorders have an increased risk for type 2 diabetes and premature death; modifiable risk factors affected by antipsychotics are obesity, insulin resistance, diabetes, and dyslipidemia.
Read More »ADA 2021: Finerenone in the Chronic Kidney Disease and Diabetes Population
Finerenone is a mineralocorticoid receptor antagonist indicated for chronic kidney disease (CKD) with type 2 diabetes. Does the use of insulin affect its performance against kidney and cardiovascular issues?
Read More »ADA 2021: Lowering of Blood Pressure and Pulse Rate by Switching from DPP-4 Inhibitor to Luseogliflozin in Patients with T2D and Hypertension
Researchers investigate the changes in ambulatory blood pressure using the antidiabetic drug in patients with type 2 diabetes and hypertension.
Read More »Gestational Diabetes Can Increase CVD Risk
GD history is linked with coronary artery calcification (CAC) in women, an indicator of atherosclerotic CVD, and a predictor of CVD clinical events.
Read More »ADA 81st Symposium: Cardiovascular and Kidney Outcomes in Efpeglenatide
With the introduction of this glucagon-like peptide-1 receptor agonist (GLP-1 RA), efpeglenatide, could we see new cardiovascular and renal benefits for patients with type 2 diabetes?
Read More »